Last Updated on July 16, 2026 by Dr. Bhagat
JOURNAL METRICS·Updated June 2026
Nature Immunology Impact Factor 2025
Nature Immunology Impact Factor 2025 is 32.5 (Q1, Immunology, SCIE). Since its launch in 2000, this journal has defined the frontier of immunological discovery, publishing work that shapes vaccine development, autoimmunity treatment, cancer immunotherapy, and our fundamental understanding of immune system biology.
IMMUNOLOGY LANDSCAPEThe Context Behind 32.5
Immunology is a field where journal impact factors carry particular weight because the research directly informs therapeutic development. When Nature Immunology publishes a paper on checkpoint inhibitor mechanisms, T-cell exhaustion, or trained immunity, pharmaceutical companies, biotech firms, and clinical trial designers pay attention. The 2025 Impact Factor of 32.5 reflects this real-world relevance; citations come not only from academic immunologists but from translational researchers, clinicians, and industry scientists.
The journal’s position as the highest-impact primary research venue in immunology gives it extraordinary editorial leverage. An h-index of 385 after 25 years of publication indicates a remarkably consistent output of highly cited papers. The CiteScore of 42.5, drawn from the four-year Scopus window, demonstrates that immunology papers in this journal accumulate citations over extended periods, consistent with the field’s pattern of building upon foundational mechanistic studies.
FULL METRICSNature Immunology at a Glance
| Metric | Value | Source / Context |
|---|---|---|
| Impact Factor (2025) | 32.5 | JCR 2025; Q1 Immunology |
| CiteScore | 42.5 | Scopus 2025 |
| SJR | 11.5 | SCImago 2025 |
| h-index | 385 | Lifetime; SCImago |
| ISSN | 1529-2908 | Springer Nature |
| Publisher | Springer Nature | Nature Portfolio |
| Established | 2000 | 25 years |
| Primary Category | Immunology | JCR Q1 |
| Scope Highlights | Innate immunity, adaptive immunity, inflammation, vaccines | Broad immunology |
| Access Model | Hybrid OA | Subscription + OA |
Key Takeaways
- 2025 IF: 32.5 (Q1 Immunology) — the top primary research journal in the field.
- CiteScore of 42.5 reflects extended citation accumulation for immunology research.
- Directly informs therapeutic development in vaccines, cancer immunotherapy, and autoimmune disease.
- h-index of 385 over 25 years demonstrates consistent publication of influential work.
- Published by Springer Nature; indexed in SCIE, PubMed, Scopus.
FREQUENTLY ASKEDFAQs on Nature Immunology
What is the Nature Immunology Impact Factor for 2025?
32.5, Q1 in Immunology.
Is it the highest immunology journal?
For primary research, yes. Nature Reviews Immunology (IF ~100+) publishes only reviews and carries a higher IF.
Does it publish clinical immunology?
It prioritizes mechanistic immunology with clinical relevance. Clinical trial reports are better suited to Journal of Clinical Investigation or Immunity.
What is the APC?
$11,390 USD for open-access research articles.
How selective is it?
Estimated acceptance rate below 10%. Substantial desk rejection at the editorial prescreening stage.
